CN104825393A - 一种硫酸头孢喹肟肺靶向脂质体制剂及其制备方法 - Google Patents
一种硫酸头孢喹肟肺靶向脂质体制剂及其制备方法 Download PDFInfo
- Publication number
- CN104825393A CN104825393A CN201510021961.5A CN201510021961A CN104825393A CN 104825393 A CN104825393 A CN 104825393A CN 201510021961 A CN201510021961 A CN 201510021961A CN 104825393 A CN104825393 A CN 104825393A
- Authority
- CN
- China
- Prior art keywords
- cefquinome sulfate
- preparation
- targeting liposomes
- pulmonary targeting
- liposomes preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 73
- KYOHRXSGUROPGY-OFNLCGNNSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrogen sulfate Chemical compound OS(O)(=O)=O.N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 KYOHRXSGUROPGY-OFNLCGNNSA-N 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 230000008685 targeting Effects 0.000 claims abstract description 39
- 239000007924 injection Substances 0.000 claims abstract description 20
- 238000002347 injection Methods 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 14
- 230000002685 pulmonary effect Effects 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 24
- 210000004072 lung Anatomy 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 14
- 230000001804 emulsifying effect Effects 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 13
- 238000004108 freeze drying Methods 0.000 claims description 12
- 150000003904 phospholipids Chemical class 0.000 claims description 12
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 11
- 238000010792 warming Methods 0.000 claims description 11
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- 239000008363 phosphate buffer Substances 0.000 claims description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 7
- 235000012000 cholesterol Nutrition 0.000 claims description 7
- 230000036571 hydration Effects 0.000 claims description 7
- 238000006703 hydration reaction Methods 0.000 claims description 7
- 239000000787 lecithin Substances 0.000 claims description 7
- 229940067606 lecithin Drugs 0.000 claims description 7
- 235000010445 lecithin Nutrition 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 235000006708 antioxidants Nutrition 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000008215 water for injection Substances 0.000 claims description 6
- 102000002322 Egg Proteins Human genes 0.000 claims description 5
- 108010000912 Egg Proteins Proteins 0.000 claims description 5
- 241000287828 Gallus gallus Species 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 238000004090 dissolution Methods 0.000 claims description 5
- 210000004907 gland Anatomy 0.000 claims description 5
- 210000004681 ovum Anatomy 0.000 claims description 5
- 238000002390 rotary evaporation Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 239000010409 thin film Substances 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- 244000068988 Glycine max Species 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- GZCGUPFRVQAUEE-KVTDHHQDSA-N aldehydo-D-mannose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KVTDHHQDSA-N 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 210000002969 egg yolk Anatomy 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000008347 soybean phospholipid Substances 0.000 claims description 2
- 125000000185 sucrose group Chemical group 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 14
- 210000000056 organ Anatomy 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 238000005538 encapsulation Methods 0.000 abstract description 2
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 239000010408 film Substances 0.000 description 5
- YWKJNRNSJKEFMK-PQFQYKRASA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 YWKJNRNSJKEFMK-PQFQYKRASA-N 0.000 description 4
- 229930186147 Cephalosporin Natural products 0.000 description 4
- 229950009592 cefquinome Drugs 0.000 description 4
- 229940124587 cephalosporin Drugs 0.000 description 4
- 150000001780 cephalosporins Chemical class 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000000385 dialysis solution Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000006509 pleuropneumonia Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000003307 reticuloendothelial effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FZIPCQLKPTZZIM-UHFFFAOYSA-N 2-oxidanylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FZIPCQLKPTZZIM-UHFFFAOYSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000606807 Glaesserella parasuis Species 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 206010071301 Perihepatitis Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 108700026460 mouse core Proteins 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- -1 under this PH Substances 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510021961.5A CN104825393B (zh) | 2015-01-16 | 2015-01-16 | 一种硫酸头孢喹肟肺靶向脂质体制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510021961.5A CN104825393B (zh) | 2015-01-16 | 2015-01-16 | 一种硫酸头孢喹肟肺靶向脂质体制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104825393A true CN104825393A (zh) | 2015-08-12 |
CN104825393B CN104825393B (zh) | 2017-11-10 |
Family
ID=53803865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510021961.5A Active CN104825393B (zh) | 2015-01-16 | 2015-01-16 | 一种硫酸头孢喹肟肺靶向脂质体制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104825393B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012084951A1 (en) * | 2010-12-22 | 2012-06-28 | Bayer Animal Health Gmbh | Enhanced immune response in bovine species |
CN103637993A (zh) * | 2013-12-20 | 2014-03-19 | 湖北领盛制药有限公司 | 单分散纳米硫酸头孢喹肟脂质体制剂及其制备方法 |
CN103784404A (zh) * | 2014-02-18 | 2014-05-14 | 临沂大学 | 一种硫酸头孢喹诺脂质体及其制备方法 |
CN104000783A (zh) * | 2014-05-14 | 2014-08-27 | 河南牧翔动物药业有限公司 | 头孢喹肟脂质体 |
-
2015
- 2015-01-16 CN CN201510021961.5A patent/CN104825393B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012084951A1 (en) * | 2010-12-22 | 2012-06-28 | Bayer Animal Health Gmbh | Enhanced immune response in bovine species |
CN103637993A (zh) * | 2013-12-20 | 2014-03-19 | 湖北领盛制药有限公司 | 单分散纳米硫酸头孢喹肟脂质体制剂及其制备方法 |
CN103784404A (zh) * | 2014-02-18 | 2014-05-14 | 临沂大学 | 一种硫酸头孢喹诺脂质体及其制备方法 |
CN104000783A (zh) * | 2014-05-14 | 2014-08-27 | 河南牧翔动物药业有限公司 | 头孢喹肟脂质体 |
Non-Patent Citations (2)
Title |
---|
刘梦娇,等: "硫酸头孢喹肟脂质体的制备工艺", 《过程工程学报》 * |
陈伟,等: "肺靶向利福平脂质体在小鼠体内的分布及抑杀菌效果观察", 《中国兽医学报》 * |
Also Published As
Publication number | Publication date |
---|---|
CN104825393B (zh) | 2017-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Apriani et al. | Formulation, characterization, and in vitro testing of azelaic acid ethosome-based cream against Propionibacterium acnes for the treatment of acne | |
CN107812197A (zh) | 一种炎症靶向的中性粒细胞递药系统及其应用 | |
CN103040748B (zh) | 一种培美曲塞二钠脂质体注射剂 | |
CN101953792B (zh) | 伊立替康纳米长循环脂质体及其制备方法 | |
CN103417479A (zh) | 一种人参皂苷Rg3脂质体及其制备方法 | |
CN100486646C (zh) | 聚乙二醇-磷脂酰乙醇胺聚合物或它的药用酸加成盐及在制药中的应用 | |
Platon et al. | Erythromycin Formulations—A Journey to Advanced Drug Delivery | |
CN103222978A (zh) | 复方磺胺甲噁唑注射液及制备方法 | |
CN101422435A (zh) | 替米考星脂质体制剂与制备方法 | |
CN104825393A (zh) | 一种硫酸头孢喹肟肺靶向脂质体制剂及其制备方法 | |
CN102579343A (zh) | 改善基于叶酸类化合物的受体型靶向制剂靶向效果的方法 | |
CN102805729A (zh) | 一种长春氟宁脂质体制剂及其制备方法 | |
CN104983695A (zh) | 一种盐酸头孢噻呋脂质体冻干剂及其制备方法 | |
CN101836995A (zh) | 复方磺胺间甲氧嘧啶钠多囊脂质体及其制备方法 | |
CN100479820C (zh) | 伊曲康唑脂质体及其制备方法 | |
CN106580878A (zh) | 一种盐酸头孢噻呋脂质体注射液及其制备方法 | |
CN104306334B (zh) | 泰万菌素脂质体及其混悬液和脂质体粉末 | |
Tatipamula et al. | Beneficial effects of liposomal formulations of lichen substances: A review | |
Otero et al. | Pharmacokinetics of enrofloxacin after single intravenous administration in sheep | |
CN114149469A (zh) | 钌配合物、狂犬病毒衍生肽和脂质体修饰的钌配合物 | |
CN102626381A (zh) | 一种拉氧头孢钠囊泡型磷脂凝胶注射剂 | |
CN102144969B (zh) | 一种依托泊苷纳米混悬液冻干制剂的制备方法 | |
CN105687136A (zh) | Peg化丹皮酚非离子表面活性剂泡囊及其制备方法 | |
CN109364256A (zh) | 一种琼脂糖胶束药物载体 | |
CN105944120B (zh) | 一种载有十二硼烷马来酰亚胺丙酰哌嗪七甲川菁硫醚盐的叶酸脂质体及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 272073 Shandong city of Jining province high tech Zone Shixian Road No. 1688 Applicant after: AMICOGEN (CHINA) BIOPHARM CO.,LTD. Address before: 272073 Shandong city of Jining province Shixian Road No. 1688 Applicant before: SHANDONG LUKANG RECORD PHARMACEUTICALS Co.,Ltd. |
|
COR | Change of bibliographic data | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A lung targeted liposome preparation of cefquinoxime sulfate and its preparation method Effective date of registration: 20231027 Granted publication date: 20171110 Pledgee: Bank of Communications Ltd. Jining branch Pledgor: AMICOGEN (CHINA) BIOPHARM CO.,LTD. Registration number: Y2023980063066 |